Triclabendazole for the treatment of fascioliasis and paragonimiasis

Expert Opinion on Investigational Drugs

Volumn 14, Issue 12, 2005, Pages 1513-1526

  Keiser, Jennifer ^a   Engels, Dirk ^b   Büscher, Gottfried ^c   Utzinger, Jürg ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fasciola hepatica; Fasciolasis; Food borne trematodiasis; Paragonimiasis; Paragonimus spp.; Triclabendazole

Indexed keywords

ALBENDAZOLE; BENZIMIDAZOLE DERIVATIVE; BITHIONOL; DEHYDROEMETINE; EMETINE; MEBENDAZOLE; NITAZOXANIDE; PRAZIQUANTEL; TRICLABENDAZOLE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BILIARY COLIC; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FASCIOLA; FASCIOLIASIS; FEVER; FOOD SAFETY; HEALTH EDUCATION; HEPATOMEGALY; HUMAN; INFECTION RISK; LIVER TOXICITY; MORBIDITY; MUSCLE WEAKNESS; NONHUMAN; PARAGONIMIASIS; PARAGONIMUS; PHOTOSENSITIVITY; PRURITUS; PUBLIC HEALTH; REVIEW; SANITATION; SINGLE DRUG DOSE; SOCIOECONOMICS; URTICARIA; VOMITING;

ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; FASCIOLIASIS; FOOD PARASITOLOGY; HUMANS; PARAGONIMIASIS;

EID: 28644450281     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.12.1513     Document Type: Review

References (105)

1. WHO: Control of foodborne trematode infections. Report of a WHO study group. WHO Technical Report Series No. 849. World Health Organization, Geneva (1995).
2. KEISER J, UTZINGER J: Emerging foodborne trematodiasis. Emerg. Inf. Dis. (2005) 11:1507-1514.
3. ESTEBAN J-G, GONZALEZ C, CURTALE F et al.: Hyperendemic fascioliasis associated with schistosomiasis in villages in the Nile Delta of Egypt. Am. J. Trop. Med. Hyg. (2003) 69:429-437.
4. KEISER J, UTZINGER J: Chemotherapy for major food-borne trematodes: a review. Expert Opin. Pharmacother. (2004) 5:1711-1726.
5. MAS-COMA S: Human fascioliasis: epidemiological patterns in human endemic areas of South America, Africa and Asia. Southeast Asian J. Trop. Med. Public Health (2004) 35:1-11.
6. SAFAR E, MIKHAIL E, BASSIOUNI G, EL-BASSIOUNI S, EL-KHOLY H: Human fascioliasis in some areas in Cairo and Giza Governorates, Egypt. J. Egypt. Soc. Parasitol. (2005) 35:181-192.
7. MARCOS L, MACO V, SAMALVIDES F, TERASHIMA A, ESPINOZA JR, GOTUZZO E: Risk factors for Fasciola hepatica infection in children: a case-control study. Trans. R. Soc. Trop. Med. Hyg. (2005) (In Press).
8. CHOI WY: Paragonimus westermani: pathogenesis and clinical features of infection. Arzneimittelforschung (1984) 34:1184-1185.
9. HASWELL-ELKINS M, LEVRI E: Food-borne trematodes. In: Manson's Tropical Diseases, Cook G, Zumla A (Eds), Saunders, London, UK (2003) 21:1471-1486.
10. SHARMA DC: Paragonimiasis causing diagnostic confusion with tuberculosis. Lancet Infect. Dis. (2005) 5:538.
11. HAWN TR, JONG EC: Update on hepatobiliary and pulmonary flukes. Curr. Infect. Dis. Rep. (1999) 1:42-433.
12. APT W, AGUILERA X, VEGA F et al.: Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am. J. Trop. Med. Hyg. (1995) 52:532-535.
13. CHEN MG, MOTT K: Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop. Dis. Bull. (1990) 87:1-38.
14. ROSSIGNOL JF, ABAZA H, FRIEDMAN H: Successful treatment of human fascioliasis with nitazoxanide. Trans. R. Soc. Trop. Med. Hyg. (1998) 92:103-104.
15. FAVENNEC L, JAVE ORTIZ J, GARGALA G et al.: Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment. Pharmacol. Ther. (2003) 17:265-270.
16. WESSELY K, REISCHIG HL, HEINERMAN M, STEMPKA R: Human fascioliasis treated with triclabendazole (Fasinex) for the first time. Trans. R. Soc. Trop. Med. Hyg. (1988) 82:743-744.
17. MASSOUD J: Fascioliasis outbreak of man and drug test (triclabendazole) in Caspaian littoral, northern part of Iran 1989. Proceedings of the 7th International Congress of Parasitology, Paris, France (1990):438.
18. WHO: Essential medicines. WHO model list 14th edition. WHO Drug Information. World Health Organization, Geneva (2005).
19. SAVIOLI L, CHITSULO L, MONTRESOR A: New opportunities for the control of fascioliasis. Bull. World Health Organ. (1999) 77:300.
20. Anonymous: Fasinex works - and that's no fluke. Ciba-Geigy J. (1985) 85.
21. BENNETT JL, KOHLER P: Fasciola hepatica: action in vitro of triclabendazole on immature and adult stages. Exp. Parasitol. (1987) 63:49-57.
22. ROBINSON CP: Triclabendazole. Drugs Today (1985) 21:227-233.
23. WHO: Triclabendazole and fascioliasis - a new drug to combat an age old disease. WHO factsheet No. 191. World Health Organization, Geneva (1998).
24. FAIRWEATHER I, BORAY JC: Fasciolicides: efficacy, actions, resistance and its management. Vet. J. (1999) 158:81-112.
25. FAIRWEATHER I, BORAY JC: Mechanism of fasciolide action and drug resistance in Fasciola hepatica. In: Fasciolosis. Dalton JP (Ed.), CABI Publishing, Dublin, Ireland (1999):225-276.
26. FAIRWEATHER I: Triclabendazole: new skills to unravel an old(ish) enigma. J. Helminthol. (2005) 79:227-234.
27. STITT AW, FAIRWEATHER I, MacKENDER RO: The effect of triclabendazole ('Fasinex') on protein synthesis by the liver fluke, Fasciola hepatica. Int. J. Parasitol. (1995) 25:421-429.
28. OVEREND DJ, BOWEN FL: Resistance of Fasciola hepatica to triclabendazole. Aust. Vet. J. (1995) 72:275-276.
29. MITCHELL GB, MARIS L, BONNIWELL MA: Triclabendazole-resistant liver fluke in Scottish sheep. Vet. Rec. (1998) 143:399.
30. MOLL L, GAASENBEEK CP, VELLEMA P, BORGSTEEDE FH: Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in the Netherlands. Vet. Parasitol. (2000) 91:153-158.
31. WALKER SM, McKINSTRY B, BORAY JC et al.: Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol. Res. (2004) 94:427-438.
32. ROBINSON MW, TRUDGETT A, HOEY EM, FAIRWEATHER I: Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology (2002) 124:325-338.
33. ROBINSON MW, LAWSON J, TRUDGETT A, HOEY EM, FAIRWEATHER I: The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol. Res. (2004) 92:205-210.
34. BOGAN JA, KINABO LD, STRONG MB, FORMICA C, GALTIER P, ALVINERIE M: Pharmacokinetics of triclabendazole in cattle, sheep, goats, horses, ponies, donkeys, pigs and man. Proceedings of the 4th Congress of the European Association for Veterinary Pharmacology and Toxicology, University of Veterinary Science, Budapest, Hungary (1988):159-163.
35. LOUTAN L, BOUVIER M, ROJANAWISUT B et al.: Single treatment of invasive fascioliasis with triclabendazole. Lancet (1989) 334:383.
36. DE RONDE T, MELANGE M, VAN BEERS B et al.: Distomatosis of the bile ducts. Value of retrograde cholangiography. Efficacy of triclabendazole. Acta Clin. Belg. (1992) 47:209-214.
37. LECAILLON JB, GODBILLON J, CAMPESTRINI J et al.: Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br. J. Clin. Pharmacol. (1998) 45:601-604.
38. HENNESSY DR, LACEY E, STEEL JW, PRICHARD RK: The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. (1987) 10:64-72.
39. McKELLAR QA, KINABO LD: The pharmacology of flukicidal drugs. Br. Vet. J. (1991) 147:306-321.
40. WHO: Evaluation of certain veterinary drug residues in food. WHO Technical Report Series No. 832. World Health Organization, Geneva (1993).
41. YOSHIMURA H: Teratogenic evaluation of triclabendazole in rats. Toxicology (1987) 43:283-287.
42. COLES GC: Anthelmintic activity of triclabendazole. J. Helminthol. (1986) 60:210-212.
43. SUHARDONO D: Triclabendazole against Fasciola hepatica infections in rats. University of Liverpool, MVS Thesis. Liverpool, UK (1987).
44. OLAECHEA FV: Trematode infections in the definitive host: studies on diagnosis, treatment, control and parasite/toxin interactions. PhD Thesis. Royal Veterinary and Agricultural University and Danish Bilharziasis Laboratory, Copenhagen, Denmark (1989).
45. GUPTA SC, CHANDRA R, YADAV SC: Efficacy of triclabendazole against experimental Fasciola gigantica infection in sheep, goat, buffalo and rabbit: a comparative study. Indian Vet. J. (1989) 66:680-682.
46. ESTUNINGSIH SE, STEVENSON P, BERIAJAYA, KNOX MR: Triclabendazole in the treatment of Fasciala gigantica infection in swamp buffalo (Bubalus bubalis). Aust. Vet. J. (1990) 67:234-235.
47. YAHIRO S, HABE S: Experimental chemotherapeutic studies of Paragonimus westermani and P. ohirai. Med. Bull. Fukuoka Univ. (1996) 23:21-25.
48. LIU Y, GAO J, WANG X, YU D, SU Q: Experimental observation of effects of triclabendazole on Paragonimus wertermani infection in dogs. Chin. Med. J. (1999) 112:345-348.
49. GAO J, LIU Y, WANG X, HU P: Triclabendazole in the treatment of Paragonimiasis skrjabini. Chin. Med. J. (2003) 116:1683-1686.
50. WEBER P, BÜSCHER G, BUTTNER DW: The effects of triclabendazole on the lung fluke, Paragonimus uterobilateralis in the experimental host Sigmodon hispidus. Trop. Med. Parasitol. (1988) 39:322-324.
51. GAO JS: Experimental observation of treating dogs infected with Clonorchis sinensis with praziquantel and triclabendazole. Chin. J. Parasit. Dis. Control (1998) 11:357.
52. SHIRAMIZU K, ABU M, HARA Y, HAIDA K: The effect of triclabendazole on canine clonorchiasis. Yamaguchi J. Vet. Med. (1989) 16:113-116.
53. KOTEL'NIKOV GA, VARENICHEV AA: Development of efficient anthelminthic drugs for domestic carnivorous animals-definitive hosts of Opisthorchis. Med. Parazitol. (1988) 2:24-26.
54. KHALIL SS: On the schistosomicidal effect of triclabendazole an experimental study. J. Egypt. Soc. Parasitol. (2000) 30:799-808.
55. AGRAWAL MC, GEORGE J, GUPTA S: Chemotherapeutic trials using Schistosoma incognitum mouse model. J. Parasit. Dis. (1999) 23:137-138.
56. TALAIE H, EMAMI H, YADEGARINIA D et al.: Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis. Clin. Exp. Pharmacol. Physiol. (2004) 31:777-782.
57. LABURTE C, MOTT K, MULL R, SEVERNE Y: Triclabendazole for fascioliasis: efficacy and tolerability of a single dose treatment. In: Infectious Diseases and Public Health, Angelico M, Rocchi G (Eds), Balaban Publishers, L'Aquila, Italy (1998):325-333.
58. RIPERT C, COUPRIE B, MOYOU R, GAILLARD F, APPRIOU M, TRIBOULEY-DURET J: Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study. Trans. R. Soc. Trop. Med. Hyg. (1992) 86:417.
59. CALVOPIÑA M, PAREDES W, GUDERIAN RH, POLTERA AA: Eficacia del triclabendazole en paragonimiasis pulmonar humana refractaria a la emetina, bithional y praziquantel. Parasitol. al dia (1993) 17:44-46.
60. CALVOPIÑA M, GUDERIAN RH, PAREDES W, CHICO M, COOPER PJ: Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans. R. Soc. Trop. Med. Hyg. (1998) 92:566-569.
61. CALVOPIÑA M, GUDERIAN RH, PAREDES W, COOPER PJ: Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis. Trans. R. Soc. Trop. Med. Hyg. (2003) 97:451-454.
62. CURTALE F, HASSANEIN YA, SAVIOLI L: Control of human fascioliasis by selective chemotherapy: design, cost and effect of the first public health, school-based intervention implemented in endemic areas of the Nile Delta, Egypt. Trans. R. Soc. Trop. Med. Hyg. (2005) 99:599-609.
63. ISHII Y, NAKAMURA-UCHIYAMA F, NAWA Y: A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole. Parasitol. Int. (2002) 51:205-209.
64. WEGNER DH: The profile of the trematodicidal compound praziquantel. Arzneimittelforschung (1984) 34:1132-1136.
65. ABDUSSALAM M, KÄFERSTEIN FK, MOTT KE: Food safety measures for the control of foodborne tremarode infections. Food Control (1995) 6:71-79.
66. EL SAYAD MH: Comparative studies on the effect of bithionol, praziquantel and triclabendazole in rabbit's fascioliasis. J. Egypt. Soc. Parasitol. (1997) 27:925-926.
67. SABA R, KORKMAZ M, INAN D et al.: Human fascioliasis. Clin. Microbiol. Infect. (2004) 10:385-387.
68. YILMAZ H, ONER AF, AKDENIZ H, ARSLAN S: The effect of triclabendazole (Fasinex) in children with fasciolosis. J. Egypt. Soc. Parasitol. (1998) 28:497-502.
69. KABAALIOGLU A, CEKEN K, SABA R, ARTAN R, CEVIKOL C, YILMAZ S: Pediatric fascioliasis: report of three cases. Turk. J. Pediatr. (2003) 45:51-54.
70. METTER K, GLOSER H, VON GAISBERG U: Fascioliasis after a stay in Turkey. Dtsch. Med. Wschr. (2000) 125:1160-1163.
71. NEAU D, LAHARIE D, LIEFERMAN F et al.: Treatment of human fascioliasis with triclabendazole. 37th Interscience Conference on Antimicrobial Agents in Chemotherapy, Ontario, Canada (1997):379.
72. LOPEZ-VELEZ R, DOMINGUEZ-CASTELLANO A, GARRON C: Successful treatment of human fascioliasis with triclabendazole. Eur. J. Clin. Microbiol. Infect. Dis. (1999) 18:525-526.
73. BECHTEL U, FEUCHT HE, HELD E, VOGL T, NOTHDURFT HD: Fasciola hepatica infection in a family: diagnosis and therapy. Dtsch. Med. Wschr. (1992) 117:978-982.
74. LE BRAS M, BEYLOT J, BIESSY H et al.: Treatment of human fasciolosis with triclabendazole. Med. Chir. Dig. (1989) 18:477-479.
75. GUICHARD D, FLORI P, RABERIN H, GALLOT B, LANG B, TRAN MANH SUNG R. Distomatose à Fasciola hepatica. A propos de quatre observations en Haute-Loire. Med. Mal. Infect. (2002) 32:190-195.
76. COUTURIER F, HIAR I, HANSMANN Y, CHRISTMANN D: Place du triclabendazole dans le traitement des fascioloses hepatiques. Med. Mal. Infect. (1999) 29:753-757.
77. MARKWALDER K, KOLLER M, GOEBEL N, WOLFF K: Fasciola hepatica infection. Successful therapy using triclabendazole. Schweiz. Med. Wochenschr. (1988) 118:1048-1052.
78. HELFENSTEIN E, KAYSER S, LOCHER G: Human fascioliasis symptoms. A case report with review of the literature. Schweiz. Rundsch. Med. Prax. (2000) 89:1427-1435.
79. CAMINAL MONTERO L, FERNANDEZ FERNANDEZ C, DE QUIROS JF, PARRA F: The treatment of human fascioliasis with triclabendazole. Rev. Clin. Esp. (1999) 199:333-335.
80. MERINO ALONSO J, AMERIGO GARCIA MJ, ALVAREZ RUBIO L, ERDOZAIN RUIZ I: Human fascioliasis with atypical severe presentation. Treatment with triclabendazole. Enferm. Infec. Microbiol. Clin. (1998) 16:28-30.
81. IGLESIAS ESCALERA G, ELVIRA PARDILLA AI, RODRIGO PALACIOS J et al.: Childhood hepatic fascioliasis treated with triclabendazole. An. Esp. Pediatr. (2002) 57:171-172,
82. PICOT S, QUERREC M, GHEZ JL, GOULLIER-FLEURET A, GRILLOT R, AMBROISE-THOMAS P: A new report of triclabendazole efficacy during invading phase fasciolasis. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:269-270.
83. MONTEMBAULT S, SERFATY L, POIROT JL, WENDUM D, PENNA C, POUPON R: Hemorrhagic ascites disclosing massive Fasciola hepatica infection. Gastroenterol. Clin. Biol. (1997) 21:785-788.
84. CHIRA O, FLORESCU P, SPARCHEZ Z et al.: Acute Fasciola hepatica infection with severe presentation: a successful treatment with triclabendazole. Rom. J. Gastroenterol. (2001) 10:321-324.
85. DOHERTY JF, PRICE N, MOODY AH, WRIGHT SG, GLYNN MJ: Fascioliasis due to imported khat. Lancet (1995) 345:462.
86. MILLAN JC, MULL R, FREISE S, RICHTER J: The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am. J. Trop. Med. Hyg. (2000) 63:264-269.
87. GRAHAM CS, BRODIE SB, WELLER PF: Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin. Infect. Dis. (2001) 33:1-5.
88. LAPOOK JD, MAGUN AM, NICKERSON KG, MELTZER JI: Sheep, watercress, and the Internet. Lancet (2000) 356:218.
89. NOYER CM, COYLE CM, WERNER C, DUPOUY-CAMET J, TANOWITZ HB, WIITNER M: Hypereosinophilia and liver mass in an immigrant. Am. J. Trop. Med. Hyg. (2002) 66:774-776.
90. LAIRD PP, BORAY JC: Human fascioliasis successfully treated with triclabendazole. Aust. N. Z. J. Med. (1992) 22:45-47.
91. HUGHES AJ, SPITHILL TW, SMITH RE, BOUTLIS CS, JOHNSON PD: Human fasciolosis acquired in an Australian urban setting. Med. J. Aust. (2003) 178:244-245.
92. JAVE OJ, ALBAN OM, SAGASTEGUI PC, SORIANO YS: Treatment of human hepatic fasciolasis with triclabendazole. Rev. Gastroenterol. Peru (1999) 19:216-220.
93. MINOPRIO JE, DONNA R, BORREMANS C et al.: A family outbreak of fluke infestation in humans of unusual distribution caused by Fasciola hepatica. Pren. Med. Argent. (1995) 82:869-877.
94. MELERO M, RIGOU RC, LLOVERAS J, GENNARO O: Hepatic fascioliasis. Uncommon cause of prolonged febrile syndrome with hypereosinophilia and hypodense images on computed tomography of the liver. Medicina (1991) 51:244-248.
95. INCANI RN, VIEIRA JM, PACHECO M, PLANCHART S, AMARISTA M, LAZDINS J: Human infection by Fasciola hepatica in Venezuela: report of a geriatric case. Invest. Clin. (2003) 44:255-260.
96. ABDUL-HADI S, CONTRERAS R, TOMBAZZI C, ALVAREZ M, MELENDEZ M: Hepatic fascioliasis: case report and review. Rev. Inst. Med. Trop. Sao Paulo (1996) 38:69-73.
97. EL-MORSHEDY H, FARGHALY A, SHARAF S, ABOU-BASHA L, BARAKAT R: Triclabendazole in the treatment of human fascioliasis: a community-based study. East. Mediterr. Health J. (1999) 5:888-894.
98. Anonymous: Triclabendazole in the treatment of established human fascioliasis. East. Mediterr. Health J. (1998) 4:244-251.
99. ABO EL HODA M, EL SAYED, IA, EL-SEDFY A: Effect of chronic fascioliasis on gall bladder and its management. J. Med. Res. Inst. (2000) 21:174-180.
100. EL-KARAKSY H, HASSANEIN B, OKASHA S, BEHAIRY B, GADALLAH I: Human fascioliasis in Egyptian children: successful treatment with triclabendazole. J. Trop. Pediatr. (1999) 45:135-138.
101. GABBOUR SN, ALLAM AF, SULTAN MM: The pulmonary performance and airway reactivity in acute and chronic fascioliasis before and after triclabendazole treatment. J. Egypt. Soc. Parasitol. (1997) 27:113-129.
102. HAMMOUDA NA, EL-MANSOURY ST, EL-AZZOUNI MZ, EL-GOHARI Y: Therapeutic effect of triclabendazole in patients with fascioliasis in Egypt. A preliminary study. J. Egypt. Soc. Parasitol. (1995) 25:137-143.
103. OSMAN MM, HELMY M, MEGEHED MA: Studies of human fasciolosis in Egypt: some serum lipid parameters before and after treatment. J. Egypt. Soc. Parasitol. (1995) 25:769-772.
104. NOZAIS JP, THOMAS I, BRICAIRE F, DANIS M, GENTILINI M: Apropos of 1 case of hepatogastric fascioliasis in Cape Verde. Bull. Soc. Pathol. Exot. (1998) 91:148-150.
105. HU P, LIU YH: A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini. Chin. J. Parasit. Dis. Cont. (2001) 19:305-307.